Development of clinical researches on prevention aromatase inhibitorassociated bone loss by zoledronic acid
- VernacularTitle:唑来磷酸防治芳香化酶抑制剂相关骨丢失临床研究进展
- Author:
Zeng WANG
;
Lin WENG
;
Bin CHENG
- Publication Type:Journal Article
- Keywords:
Zoledronic acid;
Aromatase inhibitors induce bone loss;
Postmenopausal women with breast cancer
- From:
Chinese Journal of Clinical Pharmacology and Therapeutics
1999;0(04):-
- CountryChina
- Language:Chinese
-
Abstract:
Aromatase inhibitors(AIs) are standard therpy for postmenopausal women with estrogen responsive breast cancers.By inhibiting the aromatase enzyme,causing decreases in endogenous estrogens,the treatment of Als is responsible for lower bone mineral density(BMD) and increased fractures.Therefore,early recognition, prevention,and/or treatment of AI-induced bone loss is needed.Zoledronic acid is specific inhibitors of osteoclasts and extensively used in bone metastasis patients.Recently, there are several trials evaluating the use of in- travenous zoledronic acid as prevention and treatment of AI-induced bone loss in postmenopausal women with breast cancer.In this article, we aim to review the use of zoledronic acid in this population including the response and safety.
